NCT01217606 - Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

DRUG

Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.

Trial Locations (1)

São Paulo